Medtronic Corporate Technologies and New Ventures
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Medtronic Corporate Technologies and New Ventures sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Medtronic Corporate Technologies and New Ventures: 4 sponsored US clinical trials, none currently recruiting.
Medtronic Corporate Technologies and New Ventures sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hepatitis C, with 1 trials.
Upper-quartile sponsor footprint
Medtronic Corporate Technologies and New Ventures sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Gastric Electrical Stimulation (GES) for the Treatment of Obesity
NCT01823705
Monitoring in Dialysis -- a Prospective, Multi-center, Single-arm, Non-randomized, Observational Study in Patients Who Are Undergoing Hemodialysis.
NCT01779856
Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C
NCT00919633
Medtronic Genetic Arrhythmia Markers for Early Detection (GAME Study)
NCT00664807
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Therapeutic Areas
How the Medtronic Corporate Technologies and New Ventures early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 4 completed (100%).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Hepatitis C (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Medtronic Corporate Technologies and New Ventures: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Medtronic Corporate Technologies and New Ventures sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Medtronic Corporate Technologies and New Ventures page
4 registered trials is a research-attention snapshot, not an endorsement of Medtronic Corporate Technologies and New Ventures or any single study.
- None of Medtronic Corporate Technologies and New Ventures's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hepatitis C is the condition Medtronic Corporate Technologies and New Ventures studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hepatitis C trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Medtronic Corporate Technologies and New Ventures pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.